

Unleashing the full potential of Electrophysiological home monitoring

Ziv Peremen, Yael Hanein

Company: X-trodes

Website: <https://xtrodes.com>

CEO name: Dr. Ziv Peremen

CATEGORY: Digital health SESSIONS Hospital at home: universities 'and hospitals' innovations

o Executive Summary X-trodes, with its groundbreaking technology developed at Tel Aviv University by Prof. Yael Hanein, revolutionizes at-home healthcare through its flexible, dry electrode patches. This innovation ushers in a new era of "Hospital at Home," facilitating high-quality, continuous electrophysiological monitoring outside traditional medical settings. With FDA clearance for its Smart Skin product, X-trodes empowers patients to monitor sleep and Ischemia from the comfort of their homes, enhancing diagnostics and treatment management without needing hospital visits. Currently seeking Series A financing, X-trodes is leading the charge in making advanced healthcare accessible and efficient, directly from home.

o Product Profile: X-trodes' home test solutions are undergoing clinical evaluation and is planned for commercialization next year. Regulatory approvals for Europe and for the US are building on existing approval for X-trodes' electrophysiologic signal acquisition.

o Business Strategy: The company is poised to disrupt the healthcare market with its Technology as a Service (TaaS) model, designed to minimize initial investments for sleep labs. By leveraging existing and evolving reimbursement codes for both in-lab and home-based sleep tests, it ensures a seamless integration into the current healthcare billing framework. This strategic approach not only secures short-term revenue through immediate service adoption but also positions the company for long-term financial growth by tapping into expanding patient demand. Further monetization avenues are explored through strategic partnerships with therapeutics vendors and agreements with private insurers, enhancing the value proposition and broadening the revenue base. This multifaceted business strategy underscores the company's commitment to revolutionizing sleep diagnostics and treatment, ensuring financial viability and market leadership.

o What's Next? the company is gearing up for pivotal studies to evaluate its innovative home sleep diagnostics and ischemia solutions, marking a significant leap towards expanding home healthcare. Future endeavors focus on the miniaturization of technology, extended monitoring durations, enhanced analytics, and the development of bespoke clinical solutions across various home healthcare domains. As it embarks on these ambitious projects, the company actively seeks Series A financing to fuel its growth and redefine home healthcare.